53 related articles for article (PubMed ID: 11189200)
1. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists.
Costa B; Colleoni M
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1103-8. PubMed ID: 11189200
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.
Chapman V
Br J Pharmacol; 1999 Aug; 127(8):1765-7. PubMed ID: 10482905
[TBL] [Abstract][Full Text] [Related]
4. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
Costa B; Vailati S; Colleoni M
Behav Pharmacol; 1999 May; 10(3):327-31. PubMed ID: 10780247
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers.
Rodríguez de Fonseca F; Roberts AJ; Bilbao A; Koob GF; Navarro M
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1109-14. PubMed ID: 11189201
[TBL] [Abstract][Full Text] [Related]
7. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments.
Rubino T; Viganò D; Zagato E; Sala M; Parolaro D
Synapse; 2000 Jan; 35(1):8-14. PubMed ID: 10579803
[TBL] [Abstract][Full Text] [Related]
8. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.
Richardson JD; Aanonsen L; Hargreaves KM
Eur J Pharmacol; 1997 Jan; 319(2-3):R3-4. PubMed ID: 9042616
[TBL] [Abstract][Full Text] [Related]
9. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.
Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F
Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544
[TBL] [Abstract][Full Text] [Related]
10. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
Cani PD; Montoya ML; Neyrinck AM; Delzenne NM; Lambert DM
Br J Nutr; 2004 Nov; 92(5):757-61. PubMed ID: 15533263
[TBL] [Abstract][Full Text] [Related]
11. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
12. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
[TBL] [Abstract][Full Text] [Related]
13. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
Compton DR; Aceto MD; Lowe J; Martin BR
J Pharmacol Exp Ther; 1996 May; 277(2):586-94. PubMed ID: 8627535
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
Lan R; Liu Q; Fan P; Lin S; Fernando SR; McCallion D; Pertwee R; Makriyannis A
J Med Chem; 1999 Feb; 42(4):769-76. PubMed ID: 10052983
[TBL] [Abstract][Full Text] [Related]
15. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
Freedland CS; Whitlow CT; Smith HR; Porrino LJ
Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
17. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.
Salussolia CL; Nalwalk JW; Hough LB
Brain Res; 2007 Jun; 1152():42-8. PubMed ID: 17433267
[TBL] [Abstract][Full Text] [Related]
18. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.
MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW
Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
20. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock.
Wagner JA; Varga K; Ellis EF; Rzigalinski BA; Martin BR; Kunos G
Nature; 1997 Dec; 390(6659):518-21. PubMed ID: 9394002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
